Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1

†Contributed equally
BMC Cancer201818:570

https://doi.org/10.1186/s12885-018-4294-9

©  The Author(s). 2018

  • Received: 12 January 2017
  • Accepted: 22 March 2018
  • Published:
Open Peer Review reports

Abstract

Background

A-disintegrin and metalloproteinases (ADAMs) are members of a family of multidomain transmembrane and secreted proteins. Specific ADAMs are upregulated in human cancers and correlated with tumor progression and poor outcome, but rarely studied in human hilar cholangiocarcinoma (HC). This study aimed to explore the expression profiles of ADAMs and their potential underlying mechanisms promoting cancer progression.

Methods

mRNA expression of ADAM-9, − 10, − 11, − 12, − 15, − 17, − 28, and − 33 was analyzed in human hilar cholangiocarcinoma (HC) samples. Immunohistochemical (IHC) analysis was used to detect the expression of ADAM-10, − 17, − 28, and FoxM1 in HC. The regulation of ADAM-17 by FoxM1 and their functional study was investigated in vivo and in vitro.

Results

ADAM-10, − 17, and − 28 were upregulated in tumors compared with matched non-cancerous tissues. IHC analysis revealed increased expression of ADAM-10, − 17, and − 28 in HC cells, and ADAM17 seems to be an independent prognostic factor. ADAM-17 is regulated by FoxM1. A decrease in the expression of ADAM-17 by silencing FoxM1 led to an inhibition of cell proliferation, tumor growth, and the production of tumor necrosis factor α. IHC analysis showed co-expression of FoxM1 and ADAM-17 in HC specimens.

Conclusions

The findings of the present study show an important role of the cross-talk among FoxM1, ADAM-17, and TNFa in HC development and progression.

Keywords

  • Hilar cholangiocarcinoma
  • FoxM1
  • ADAMs
  • ADAM-17
  • Prognosis

Background

Hilar cholangiocarcinoma (HC), also known as Klatskin tumor, is a complex and devastating malignancy of the bile duct [1]. Surgical resection is the most effective management for HC and offers a relatively long-term survival when performed during early stages of cancer [2]. Unfortunately, most HC patients are diagnosed at later stages, when the tumor has metastasized to major structures surrounding the bile duct [1, 3]. Even after complete resection, recurrence has been observed in 50%–70% of cases [1]. It has been estimated that the 5-year survival rate after R0 resection of HC ranges from 10% to 40% [1]. In addition, the mechanisms underlying HC development and progression have not been fully elucidated, which in turn limits the use of targeted therapy. Therefore, demonstrating the molecular alterations and regulatory mechanisms involved in the carcinogenesis of HC is imperative.

A-disintegrin and metalloproteinases (ADAMs) participate in various biological functions, including fertilization, cell adhesion and migration, and proteolysis [4, 5]. There is growing evidence that specific ADAMs are dysregulated in human solid cancers [6–8]. These ADAMs regulate the activation of growth factors (e.g., EGF, TGF-a), cytokines (TNF-a), and integrins, which in turn promote tumor growth and metastasis [9]. Moreover, targeting specific ADAMs by selective ADAM inhibitors is considered as a promising therapeutic strategy [10]. In HC, however, the expression profiles of ADAMs and their regulation are not well understood.

Therefore, we aimed to explore the expression levels of specific ADAMs in HC and to determine the clinical roles of upregulated ADAMs in cancers. Furthermore, we identified the most valuable ADAM, as well as analyzed its function and potential regulatory mechanism.

Methods

Patient samples and cell culture

Five fresh paired HC and the adjacent non-cancerous tissues were used in the determination of expression levels of specific ADAMs by using RT-PCR. Tissue microarrays of 49 resected HC specimens and 15 matched non-cancerous bile duct tissues were constructed as previously described [11]. All these patients had detailed clinical history and follow-up information (Table 1). The institutional review boards of the Eastern Hepatobiliary Hospital and Changhai Hospital approved this study, and informed consents were obtained from each patient or his or her guardians.
Table 1

Association between ADAM-10, ADAM-17, ADAM-28, and FoxM1 expression and clinical variables of hilar cholangiocarcinoma

Variables

N

ADAM-10

P

ADAM-17

P

ADAM-28

P

FoxM1

P

Gender

 Male

38

27

0.866

23

0.309

22

0.235

20

0.049

 Female

16

11

 

12

 

12

 

13

 

Size

  ≤ 3 cm

21

12

0.089

9

0.007

10

0.063

9

0.028

 >3 cm

33

26

 

26

 

24

 

24

 

T stage

 T1–3

7

2

0.009

3

0.192

3

0.238

3

0.288

 T4

47

36

 

32

 

31

 

30

 

N stage

 N0

18

10

0.092

9

0.107

9

0.163

10

0.554

 N1–2

36

28

 

26

 

25

 

23

 

Differentiation

 High/moderate

40

30

0.208

27

0.485

24

0.446

22

0.119

 low/undifferentiated

14

8

 

8

 

10

 

11

 

TNM

 I/II

22

11

0.007

9

0.002

10

0.027

11

0.165

 III/IV

32

27

 

26

 

24

 

22

 

Human cholangiocarcinoma cell lines (QBC939 and RBE) and HEK293T cell lines were obtained from the Cell Center of the Chinese Academy of Sciences. The conditions for cell culture were as described in a previous report [11].

Real-time RT-PCR

The relative expression levels of specific ADAMs were detected by real-time RT-PCR by using a SYBR Premix Ex Taq (Perfect real-time) kit (Takara,Japan) in a Rotor Gene 3000 system (Corbet Research, Sydney, Australia). The sequences of the primers for these ADAMs and those of the internal control, GAPDH, are listed in Additional file 1: Table S1.

Western blot analysis

Western blot analysis was used to detect the protein levels of FoxM1 (K19, Santa Cruz Biotechnology), ADAM-17 (H300, Santa Cruz Biotechnology), and TNFa (10602-RP02, Sino Biological, Inc.) according to standard procedures [12–14].

Measurement of TNFαrelease

The levels of TNFa were measured in cell-free supernatants of stably transfected FoxM1-overexpressing RBE cells, FoxM1-shRNA QBC939 cells, and the control cells. Quantitation was performed with ELISA detection kits (EH009–96, Excell BIO) following protocols described by the manufacturer [15].

Immunohistochemical analysis and scoring

Tissue microarrays containing HC (n = 49) and matched non-cancerous bile duct tissues and the fresh tissues (n = 5) were immunostained with antibodies against ADAM-10 (1:100), ADAM-17 (1:100), ADAM-28 (1:100, H102, Santa Cruz Biotechnology), and FoxM1 (1:150) according standard protocols. Tissue sections were microwave-treated in citrate buffer (PH 6.0) at 99 °C for 4 min. The sections were placed in 3% H2O2 for 10 min and then washed three times with phosphate-buffered saline (PBS) buffer for 3 min. Normal goat serum was used to block antibody at room temperature for 10 min. The primary antibodies were incubated at 4 °C for 24 h. Biotinylated anti-mouse/rabbit immunoglobulin was used as the second antibody. 3, 3-Diaminobenzidine (DAB) was used as a chromogen. The sections were counter-stained with hematoxylin [16]. An isotype Ig antibody was used as a negative control (Fig. 1b).
Fig. 1
Fig. 1

Expression patterns of ADAM proteases in human hilar cholangiocarcinoma and non-cancerous tissues. a Normalized mRNA values of specific ADAMs in hilar cholangiocarcinoma tissues compared to non-cancerous tissues. The fold changes (y axis) are calculated as the log ratio of the relative amounts of mRNA in tumor/non-cancerous tissues. b A negative immunohistochemical control using an isotype Ig antibody. c, d, e Expression of ADAM-10 (c), ADAM-17 (d), and ADAM-28 (e) proteins in non-cancerous tissues (C1, D1, and E1) and hilar cholangiocarcinoma (C2, D2, and E2) by immunohistochemical analysis. Magnification: 200×. Graphical representation of the difference in the intensity of ADAM-10 (C3), ADAM-17 (D3), and ADAM-28 (E3) immunostaining in tumor (T) and normal (N) tissues. *P < 0.01

Two individuals (G.Y. and Y.C.) independently reviewed the stained sections and scored each case. ADAM expression was scored in epithelial cells (normal or tumor cells). The intensity and percentage of positive tumor cells was determined by using a semi-quantitative scoring system [11]. The mean percentage of positive tumor cells was calculated in five areas of a given sample at a magnification of × 400 and scored from 0 to 1 (0–100%). The intensity of immunostaining was scored as 0 for negative, 1 for weak, 2 for moderate, and 3 for strong. Therefore, a weighted score was generated for each case, ranging from 0 (0% of cells stained) to 300 (100% of cells stained at 3+ intensity) [17]. Finally, the score < 75 was defined as negative/low expression.

Plasmids and transfections

The pcDNA3.1-FoxM1B and FoxM1-shRNA plasmids were gifts from Prof. Sunyun Huang (MD Anderson Cancer Center, Houston, TX, USA) [18]. QBC cells were transfected with 50 nM of the FoxM1 plasmid or control, whereas RBE cells were infected with 50 nM of shRNA targeting FoxM1 or 50 nM of scrambled siRNA, according to the manufacturer’s instructions. The Fugene-6 system (Qiagen, Crawley, UK) was used for transfection.

Cell proliferation assay

Approximately 24 h after transfection or infection, the tumor cells were digested and seeded into 96-well plates at a density of 2000 cells per well. CCK8 assays (Dojindo Kumamoto, Japan) were conducted to measure the final absorbance at specific time points.

Flow cytometric analysis

Flow cytometric analysis was carried out to determine the effects of FoxM1 on cell cycle distribution. Briefly, stable FoxM1-shRNA infected cells and stable FoxM1-overexpression cells were harvested by trypsinization and fixed with 70% ethanol, and measured according to the manufacturer’s protocol (KEY GEN, Nanjing, China). The cell cycle distribution was then analyzed by flow cytometry (FACSCalibur, BD Biosciences, Bedford, MA).

Subcutaneous tumor growth

Stable FoxM1-shRNA infected cells (density: 1 × 107) were subcutaneously injected into female BALB/c nude mice. Two weeks after injection, the mice were sacrificed, and the tumor was excised, measured, and weighed. Tumor volume (mm3) was calculated as V = 0.52 (length × width × depth).

Statistical analysis

SPSS and GraphPad Prism 5.0 were used in data analysis and for generating representative images. The t-test was used to determine the significance of the in vitro results. The χ2 test was used to analyze the categorical data. The Kaplan-Meier assay was used to estimate survival rates. The Cox proportional hazards model was used to assess predictors that were related to tumor recurrence and overall survival. p < 0.05 was considered as significant [19].

Results

Expression profiles of specific ADAMs in HC

Because ADAMs function in the proteolytic processing of other transmembrane proteins, we investigated the expression patterns of proteinase-type ADAM molecules (ADAM8, − 9, − 10, − 12, − 15, − 17, − 19, − 28, and − 33) in HC. Figure 1a shows that the mean mRNA levels of ADAM-10, ADAM-17, ADAM-19, ADAM-28, and ADAM-33 were higher in the tumor samples compared to that in non-cancerous bile duct tissues.

Relationship between ADAM-10, ADAM-17, and ADAM-28 expression and clinical variables of patients with HC

Considering the importance of ADAM-10, ADAM-17, and ADAM-28 in cancer progression [9], we detected their expression in HC by immunohistochemistry. ADAM-10, ADAM-17, and ADAM-28 were localized to the cytoplasm. The non-cancerous bile ducts showed negative or weak staining for ADAM-10, ADAM-17, and ADAM-28, whereas most cancer cells showed strong staining for these three proteins (Fig. 1b-e). The rate of ADAM-10, ADAM-17, and ADAM-28 high expression in HC was 70.4% (38/54), 64.8% (35/54), and 63.0% (34/54), respectively. Further analysis showed a significant correlation between ADAM-10 overexpression and T stage (P = 0.009) and AJCC TNM stage (P = 0.007), ADAM-17 and larger tumor size (P = 0.007) and AJCC TNM stage (P = 0.002), ADAM-28 and AJCC TNM stage (P = 0.027) (Table 1).

Kaplan-Meier analysis revealed that T stage, regional lymph node metastasis, residual tumor, ADAM-10, ADAM-17, and ADAM-28 were associated with shorter time to tumor progression/recurrence (TTP). All the above covariates were enrolled in the following multivariate analysis. Multivariate analysis showed that the T stage and regional lymph node metastasis were independent factors in predicting tumor recurrence (Fig. 2, Table 2). As for overall survival, T stage, regional lymph node metastasis, residual tumor, ADAM-10, and ADAM-17 were associated with decreased overall survival for patients with HC. Cox proportional hazards model showed that T stage, regional lymph node metastasis, and ADAM-17 were independent prognostic indicators for patients with HC (Fig. 2, Table 3).
Fig. 2
Fig. 2

Kaplan-Meier survival patients with hilar cholangiocarcinoma based on ADAM-28, ADAM-10, and ADAM-17 expression. a, b, c Cancer overexpressing ADAM-28 (A), ADAM-10 (B), and ADAM-17 (C) showed a higher chance for recurrence than those who did not (ADAM-28: Neg. vs. Pos.: 26mon vs. 15mon, P = 0.050; ADAM-10: Neg. vs. Pos.: 41mon vs. 17mon, P = 0.020; AD1 M-17: Neg. vs. Pos.: 39mon vs. 17mon, P = 0.010). (A1, B1, C1) Patients overexpressing ADAM-28 (A1), ADAM-10 (B1), and ADAM-17 (C1) showed a decreased survival duration compared to patients who did not (ADAM-28: Neg. vs. Pos.: 26mon vs. 17mon, P = 0.074; ADAM-10: Neg. vs. Pos.: 50mon vs. 17mon, P = 0.010; AD1 M-17: Neg. vs. Pos.: 42mon vs. 15mon, P = 0.003)

Table 2

Univariate and Multivariate Analysis of Variables Associated with Recurrence in Patients with hilar cholangiocarcinoma

Variable

No.a

TTP (months)

P

P

HR (multivariate)

95% CI

(univariate)

(multivariate)

T stage

 T1–3

7

52

0.002

0.025

0.094

0.012–0.740

 T4

46

17

    

Regional lymph nodes positive

 No

18

39

0.014

0.021

0.361

0.152–0.858

 Yes

35

15

    

R

 R0

24

37

0.04

0.926

1.037

0.482–2.232

 R1

29

17

    

ADAM10

 Negative

15

41

0.002

0.488

0.614

0.155–2.437

 Positive

38

17

    

ADAM17

 Negative

18

39

0.01

0.485

0.671

0.218–2.059

 Positive

35

17

    

ADAM28

 Negative

19

26

0.05

0.639

0.813

0.343–1.930

 Positive

34

17

    

a The detailed information of tumor recurrence of one case was not available

Table 3

Univariate and Multivariate Analysis of Variables Associated with Overall Survival (OS) in Patients with hilar cholangiocarcinoma

Variable

No.

OS(months)

P

P

HR (multivariate)

95% CI

(univariate)

(multivariate)

Tumor stage

 T1–3

7

50

0.004

0.02

0.135

0.025–0.730

 T4

47

17

    

Regional lymph nodes positive

 No

18

42

0.006

0.023

0.384

0.168–0.875

 Yes

36

14

    

R

 R0

24

26

0.024

0.784

0.903

0.437–1.869

 R1–2

30

16

    

ADAM10

 Negative

16

50

0.01

0.589

1.359

0.447–4.135

 Positive

38

17

    

ADAM17

 Negative

19

42

0.003

0.035

0.318

0.109–0.924

 Positive

35

15

    

FoxM1B regulates ADAM-17 expression in human HC cell lines

Because deletion of FoxM1 induces the downregulation of ADAM-17 [20], we tried to investigate whether ADAM-17 could be regulated by FoxM1 in HC. As expected, overexpression of FoxM1B in RBE cells resulted in an increase in the expression of ADAM-17 and promotion of cell proliferation (Fig. 3a). Silencing of FoxM1 led to a decrease in the expression of ADAM-17, inhibition of cell proliferation and cell cycle arrest, as shown by the accumulation of cells in S phase (Fig. 3b). This might be associated with a change in S phase-related protein cyclin A, which is required to phosphorylate and activate FoxM1 during G(2) phase [21–23]. Next, we examined whether the FoxM1-ADAM-17 axis played a key role on tumor growth by downregulating the expression of FoxM1 and ADAM-17. Fig. 3c shows that tumor volumes were significantly smaller in the FoxM1-knockdown group than that in the control group. Accordingly, IHC staining showed a lower expression of ADAM-17 in FoxM1-knockdown tumors than that in the control tumors.
Fig. 3
Fig. 3

FoxM1 activates ADAM-17 and promotes cell proliferation in vitro and tumor growth in vivo. a RBE cells transfected with FoxM1 and control vector after 48 h; FoxM1 and ADAM17 protein expression (upper) were detected by Western blot analysis, and cell viability was analyzed by CCK8 assay (lower). b QBC939 cells transfected with FoxM1-shRNA and scrambled control after 48 h; FoxM1 and ADAM-17 protein expression (upper) were detected by Western blot analysis, cell viability was analyzed by CCK8 assay (middle), cell cycle distribution was measured by flow cytometric analysis (lower). All the above experiments were repeated three times. c QBC939 cells (1 × 107 per mouse) transfected with FoxM1-shRNA or control shRNA were subcutaneously injected into nude mice (n = 5). Resected tumor pictures (left), graphical representation of tumor volumes (right), and staining of ADAM17 in the two groups. OE, overexpression. *p < 0.05, **p < 0.01 as compared to control

Correlation between FoxM1 expression and ADAM-17 expression

Next, we detected FoxM1 expression in the 54 cases by immunohistochemistry and analyzed its association with clinical variables and ADAM-17. FoxM1 was overexpressed in 33 of 54 (61.1%) HC cases and was significantly correlated to larger tumor size (P = 0.028) (Table 1). IHC staining showed that FoxM1 and ADAM-17 were co-overexpressed in 48.1% (26/54) cases, co-underexpressed in 22.2% (12/54) cases. Only 16 cases of 54 (29.6%) showed un-uniform expression of FoxM1 and ADAM-17(Fig. 4a and b). A significant correlation between FoxM1 expression and ADAM-17 expression was observed (P = 0.007) (Fig. 4b). Moreover, patients who showed FoxM1 overexpression had a higher frequency of recurrence than those who did not express this protein (Fig. 4c). Similarly, patients who exhibited FoxM1 overexpression had relatively shorter survival duration than those who did not show FoxM1 expression (Fig. 4c).
Fig. 4
Fig. 4

Positive correlations between FoxM1 and ADAM-17 in human hilar cholangiocarcinoma samples. a Representative expression of FoxM1 (upper) and ADAM-17 (lower) proteins in tumor samples. Magnification: 40× (left), 200× (right). b Kaplan-Meier survival curves of tumor recurrence (left, Neg. vs. Pos.: 30mon vs. 12mon, P = 0.011) and overall survival (right, Neg. vs. Pos.: 40mon vs. 13mon, P < 0.001) for patients with hilar cholangiocarcinoma based on FoxM1 expression. c The correlation between FoxM1 and ADAM-17 expression as determined by Pearson’s correlation test

FoxM1 regulates ADAM-17 to promote TNFa production and secretion

In cell adhesion, TNFa undergoes proteolytic processing by ADAM-17. In the present study, we detected the protein expression of TNFa in tumor cell lysates and cell supernatants after FoxM1 was overexpressed or silenced. Undoubtedly, the overexpression of FoxM1 increased the expression of ADAM-17, as well as TNFa expression and cleavage (Fig. 5a). Furthermore, silencing of FoxM1 decreased the expression of ADAM-17, as well as the expression and secretion of TNFa (Fig. 5b).
Fig. 5
Fig. 5

FoxM1 regulates ADAM-17 expression promoting TNFa expression and cleavage. a RBE cells were stably transfected with FoxM1 and protein levels of FoxM1, ADAM-17, and TNFa were detected in the whole cell lysates by Western blotting (upper) and TNFa was detected by ELISA in the supernatants (lower). b QBC 939 cells were stably transfected with FoxM1-shRNA and protein levels of FoxM1, ADAM-17, and TNFa were detected in the whole cell lysates by Western blotting (upper) and TNFa was detected by ELISA in the supernatants (lower). OE: overexpression. *P < 0.05; ***P < 0.001

Discussion

In the present study, we systemically analyzed the expression of certain proteinase-type ADAMs mRNA in HC and explored the clinical values of ADAM-10, ADAM-17, and ADAM28 in HC. ADAM-17 was regulated by FoxM1. FoxM1 was significantly correlated to ADAM-17 overexpression. The upregulation of FoxM1 and ADAM-17 led to an increase in the activities of cell proliferation and tumor growth, as well as TNFa expression and cleavage, whereas the downregulation of FoxM1 and ADAM-17 showed the opposite results. These findings thus indicate that ADAM-17 may be utilized as an independent prognostic factor in patients with HC. The results also illustrate the critical role of FoxM1/ADAM-17/TNFa in the development and progression of HC.

ADAMs possess an a-disintegrin and metalloprotease domain, indicating its potential role in the progression of human cancers via cell adhesion and protease activities. Consistent with this implication, increasing evidences have suggested that specific ADAMs, including ADAM-9, ADAM-12, ADAM-17, ADAM-28, ADAM-33, were upregulated in various human solid cancers and correlated to the malignant behaviors of these tumors [24–29]. Certain ADAMs may also be utilized as predictors of patients’ outcomes. However, the expression or regulation of ADAMs in HC was not comprehensively examined. Here, we gave the first evidences that certain ADAMs such as ADAM-10, ADAM-17, ADAM-19, ADAM-28, and ADAM-33, were evaluated in HC. Among these, ADAM-10, ADAM-17, and ADAM-28 were the mostly well-studied molecules. We then analyzed their clinical indications in HC. The protein expression levels of ADAM-10, ADAM-17, and ADAM-28 were upregulated in the HC tissues and correlated significantly with disease progression. Interestingly, patients showing ADAM overexpression showed shorter times to recurrence and a poor outcome. These findings suggest that ADAMs are involved in tumor formation and progression of HC.

ADAM activities can be activated by TGF-ß, TPA, PKCδ, and MMPs and inactivated by TIMPs [9]. Considering the importance of ADAM-17 in tumor progression and predicting patient outcomes, we explored the underlying mechanisms of ADAM-17 upregulation. Previous reports have shown that ADAM-17 mRNA levels were remarkably reduced in the lungs of knockout FoxM1 mice [20]. Therefore, it is assumed that FoxM1, a transcription factor, could regulate the expression of ADAM-17. In the present study, we confirmed that FoxM1 regulated ADAM-17 expression in vivo and in vitro, leading to enhanced cell proliferation and tumor growth. Further investigation indicated that FoxM1 is co-expressed with ADAM-17 in the majority of HC samples. These findings offer evidence that FoxM1 regulates ADAM-17 expression, which may significantly contribute to the invasiveness and malignant potential of cancer cells.

ADAM-17, known as TNFa-converting enzyme (TACE), can activate the tissue inflammatory cytokine, Pro-tumor Necrosis Factor a (Pro-TNFa), to biologically active, free TNFa [30, 31]. In the present study, the enhanced expression of ADAM-17 by FoxM1 increased TNFa production and cleavage, whereas the decreased expression of ADAM-17 by FoxM1-shRNA resulted in a decrease in TNFa production and cleavage. Activated TNFa in turn releases various cytokines (such as interleukins), which promotes cell viability and cancer progression [32]. This result further confirmed that FoxM1 is a key regulator of the ADAM-17/TNFa axis in cancer cell proliferation and progression.

Conclusions

In summary, we showed that specific ADAMs are overexpressed in HC and correlated with tumor invasion and disease progression. ADAM-17 is an independent prognostic marker for patients with HC. FoxM1 regulates the expression of ADAM-17 and then induced TNFa production and cleavage. Therefore, the FoxM1/ADAM-17/TNFa axis might be a promising targeted pathway for the development of therapeutic strategies of HC.

Abbreviations

ADAMs: 

A-disintegrin and metalloproteinases

HC: 

Hilar cholangiocarcinoma

IHC: 

Immunohistochemical

Declarations

Acknowledgements

We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

Funding

Shanghai Pujiang Program (13PJD002) funded in the design of the study and the cell biology study; The Natural Science Foundation of China (81572856) funded in interpretation of data and in writing the manuscript; the Young Start-up Foundation of Changzheng Hospital (2015CZQN07) funded in the ELISA assay; and the International S&T Cooperation Program of China (2014DFA33010) funded in samples collection and analysis.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

XJ and YC participated in the design of the study, carried out the mRNA and protein expression of ADAMs and FoxM1 in cancers and analyzed the data. WY and JQ participated in the collection of tumor samples, acquisition of the follow-up information and interpretation of these data. XJ, YC, and WF performed the cell biology study and the Western Blotting test. PW assisted in digitizing all pathological slides and revising it by carrying out the cell cycle test and Elisa assay. WF and GY participated in its design and coordination, and supervised the study. GY drafted the manuscript. XJ, WY, JQ and YC contributed equally to this work. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The institutional review boards of the Eastern Hepatobiliary Hospital and Changhai Hospital approved this study and written informed consents were obtained from each patient or his or her guardians.

All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and was approved by the Animal Ethics Committee of the Second Military Medical University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China
(2)
Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China
(3)
Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Shanghai, China
(4)
Department of Pathology, Changhai Hospital, Shanghai, China
(5)
Department of Oncology, Fuzhou General Hospital, Fuzhou, Fujian Province, China
(6)
Department of Medical Oncology, Changzheng Hospital, Shanghai, China

References

  1. Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3(1):18–34.PubMedPubMed CentralGoogle Scholar
  2. Tsuchikawa T, Hirano S, Okamura K, Matsumoto J, Tamoto E, Murakami S, Nakamura T, Ebihara Y, Kurashima Y, Shichinohe T. Advances in the surgical treatment of hilar cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2015;9(3):369–74.View ArticlePubMedGoogle Scholar
  3. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):221–32.View ArticlePubMedGoogle Scholar
  4. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Asp Med. 2008;29(5):258–89.View ArticleGoogle Scholar
  5. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005;6(1):32–43.View ArticlePubMedGoogle Scholar
  6. Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009;15(4):1140–4.View ArticlePubMedGoogle Scholar
  7. Aydin D, Bilici A, Yavuzer D, Kefeli U, Tan A, Ercelep O, Mert A, Yuksel S, Ozcelik M, Isik D, et al. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy. Clin Transl Oncol. 2015;17(8):604–11.View ArticlePubMedGoogle Scholar
  8. Chen J, Chen X, Wang F, Gao H, Hu W. Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway. Neurol Sci. 2015;36(3):435–40.View ArticlePubMedGoogle Scholar
  9. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98(5):621–8.View ArticlePubMedGoogle Scholar
  10. Mullooly M, McGowan P, Crown J, Duffy MJ. The ADAMs family of proteases as targets for the treatment of Cancer. Cancer Biol Ther. 2016;17(8):870–80.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Yu G, Yu W, Jin G, Xu D, Chen Y, Xia T, Yu A, Fang W, Zhang X, Li Z, et al. PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma. Mol Cancer. 2015;14(1):193.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Huang H, Liu Y, Wang L, Li W. Age-related macular degeneration phenotypes are associated with increased tumor necrosis-alpha and subretinal immune cells in aged Cxcr5 knockout mice. PLoS One. 2017;12(3):e0173716.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Wang L, Cano M, Handa JT. p62 provides dual cytoprotection against oxidative stress in the retinal pigment epithelium. Biochim Biophys Acta. 2014;1843(7):1248–58.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Schwarz J, Broder C, Helmstetter A, Schmidt S, Yan I, Muller M, Schmidt-Arras D, Becker-Pauly C, Koch-Nolte F, Mittrucker HW, et al. Short-term TNFalpha shedding is independent of cytoplasmic phosphorylation or furin cleavage of ADAM17. Biochim Biophys Acta. 2013;1833(12):3355–67.View ArticlePubMedGoogle Scholar
  15. Lee M, McGeer EG, McGeer PL. Sodium thiosulfate attenuates glial-mediated neuroinflammation in degenerative neurological diseases. J Neuroinflammation. 2016;13:32.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Liu K, Wang G, Ding H, Chen Y, Yu G, Wang J. Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC Cancer. 2010;10:428.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Gao Y, Chen Y, Xu D, Wang J, Yu G. Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers. BMC Cancer. 2014;14:520.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Yu G, Zhou A, Xue J, Huang C, Zhang X, Kang SH, Chiu WT, Tan C, Xie K, Wang J, et al. FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway. Oncotarget. 2015;6(13):11281–94.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Chen Y, Cha Z, Fang W, Qian B, Yu W, Li W, Yu G, Gao Y. The prognostic potential and oncogenic effects of PRR11 expression in hilar cholangiocarcinoma. Oncotarget. 2015;6(24):20419–33.PubMedPubMed CentralGoogle Scholar
  20. Kim IM, Ramakrishna S, Gusarova GA, Yoder HM, Costa RH, Kalinichenko VV. The forkhead box m1 transcription factor is essential for embryonic development of pulmonary vasculature. J Biol Chem. 2005;280(23):22278–86.View ArticlePubMedGoogle Scholar
  21. Sullivan C, Liu Y, Shen J, Curtis A, Newman C, Hock JM, Li X. Novel interactions between FOXM1 and CDC25A regulate the cell cycle. PLoS One. 2012;7(12):e51277.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Preya UH, Lee KT, Kim NJ, Lee JY, Jang DS, Choi JH. The natural terthiophene alpha-terthienylmethanol induces S phase cell cycle arrest of human ovarian cancer cells via the generation of ROS stress. Chem Biol Interact. 2017;272:72–9.View ArticlePubMedGoogle Scholar
  23. Laoukili J, Alvarez M, Meijer LA, Stahl M, Mohammed S, Kleij L, Heck AJ, Medema RH. Activation of FoxM1 during G2 requires cyclin a/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain. Mol Cell Biol. 2008;28(9):3076–87.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Sharma A, Bender S, Zimmermann M, Riesterer O, Broggini-Tenzer A, Pruschy MN. Secretome signature identifies ADAM17 as novel target for Radiosensitization of non-small cell lung Cancer. Clin Cancer Res. 2016;22(17):4428–39.View ArticlePubMedGoogle Scholar
  25. Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M. Immunohistochemical study on ADAM33 in sinonasal inverted papillomas and squamous cell carcinomas of the larynx. Arch Med Sci. 2016;12(1):89–94.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Zhang XH, Wang CC, Jiang Q, Yang SM, Jiang H, Lu J, et al. ADAM28 overexpression regulated via the PI3K/Akt pathway is associated with relapse in de novo adult B-cell acute lymphoblastic leukemia. Leuk Res. 2015. https://doi.org/10.1016/j.leukres.2015.08.006.
  27. Mullooly M, PM MG, Kennedy SA, Madden SF, Crown J, O’donovan N, Duffy MJ. ADAM10: a new player in breast cancer progression? Br J Cancer. 2015;113(6):945–51.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS, Shin YK, Zhang X, Park KH, Park SW, Chung HC, et al. The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Mol Cancer Ther. 2014;13(12):3074–85.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, Cataldo D. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 2008;90(2):369–79.View ArticlePubMedGoogle Scholar
  30. Hurtado O, Lizasoain I, Fernandez-Tome P, Alvarez-Barrientos A, Leza JC, Lorenzo P, Moro MA. TACE/ADAM17-TNF-alpha pathway in rat cortical cultures after exposure to oxygen-glucose deprivation or glutamate. J Cereb Blood Flow Metab. 2002;22(5):576–85.View ArticlePubMedGoogle Scholar
  31. Condon TP, Flournoy S, Sawyer GJ, Baker BF, Kishimoto TK, Bennett CF. ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes. Antisense Nucleic Acid Drug Dev. 2001;11(2):107–16.View ArticlePubMedGoogle Scholar
  32. Esquivel-Velazquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interf Cytokine Res. 2015;35(1):1–16.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us